Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF May 11, 2012 Issue | Archived Issues

New FDA alerts

Pharmacy focus

The U.S. Food and Drug Administration issued updates and warnings for phenytoin, fosphenytoin, dronedarone, aliskiren and other drugs.

» Read more


Physician news

David Rimoin, MD, PhD, named an American College of Physicians master, Ilana Cass, MD, selected for the Executive Leadership in Academic Medicine fellowship, a Kawasaki disease study by Moshe Arditi, MD, honored at conference, and Robert H. Baloh, MD, PhD, received ALS Association award.

» Read more


Meetings and events


Grand rounds

Click here to view upcoming Grand Rounds.


Upcoming CME conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - May 2012 (PDF)

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

New FDA alerts

The U.S. Food and Drug Administration issued updates and warnings for phenytoin fosphenytoin, dronedarone, aliskiren and other drugs.

Cardiovascular side effects from rapid infusion of fosphenytoin (Cerebyx®) or phenytoin (Dilantin®)

The package labeling of these two drugs has been updated to include a boxed warning for infusion rated cardiovascular side effects such as severe hypotension and arrhythmias. The manufacturer recommends that the infusion rate for fosphenytoin should not exceed 150mg PE/min and that the infusion rate for phenytoin should not exceed 50mg/min for adults and 1-3mg/kg/min (maximum 50mg/min) for pediatric patients.

In addition, cardiac monitoring is recommended during and after administration of fosphenytoin or phenytoin.

Boxed warning update for dronedarone (Multaq®)

The boxed warning has been updated to include information regarding increased risk of death, stroke and heart failure in patients with either decompensated heart failure or permanent atrial fibrillation. In these patients and in patients with NYHA class IV heart failure, dronedarone is contraindicated.

Brentuximab (Adcetris®) and progressive multifocal leukoencephalopathy

A new boxed warning was added to the labeling of Adcetris® due to reports of progressive multifocal leukoencephalopathy (PML). It was recommended that the doses be put on hold if PML is suspected. The drug should be stopped if a diagnosis of PML is confirmed.

Fetal toxicity with ACEi, ARB and Aliskiren

Due to the risk of injury and death to developing fetus, a boxed warning has been added to recommend discontinuation of ACE inhibitor, ARB and aliskiren once pregnancy is detected.

Radiation exposure with rubidium Rb 82 generator (Cardiogen-82®)

The labeling of Cardiogen-82® now includes a boxed warning for unintended radiation exposure when levels of Sr-82 or Sr-85 exceed limits.It is therefore recommended to perform generator eluate tests on a routine basis and to stop using the generator at the expiration limit.

New contraindications with itraconazole (Sporanox®)

As a result of the risk for serious and potentially life threatening adverse effects from increased drug levels, the use of the following medications in combination with itraconazole capsule or oral solution is contraindicated: cisapride, oral midazolam, nisoldipine, felodipine, pimozide, quinidine, dofetilide, triazolam, levaacetylmethadol, lovastatin, simvastatin, ergot alkaloids such as dihydroergotamine, ergometrine, ergotamine and methylergometrine, and methadone.